FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid

Journal of Immunology

Volumn 187, Issue 1, 2011, Pages 553-560

  Messingham, Kelly N ^a   Srikantha, Rupasree ^a   DeGueme, Amy M ^b   Fairley, Janet A ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BASEMENT MEMBRANE; BULLOUS PEMPHIGOID; CELL COUNT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEMIDESMOSOME; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOPATHOGENESIS; INTERNALIZATION; KERATINOCYTE; PRIORITY JOURNAL; SKIN CULTURE;

AUTOANTIBODIES; AUTOANTIGENS; BASEMENT MEMBRANE; BINDING SITES, ANTIBODY; CELL CULTURE TECHNIQUES; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; KERATINOCYTES; NON-FIBRILLAR COLLAGENS; ORGAN CULTURE TECHNIQUES; PEMPHIGOID, BULLOUS; RECEPTORS, FC; SKIN;

EID: 79960383879     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001753     Document Type: Article

References (51)

1. Jordon, R. E., E. H. Beutner, E. Witebsky, G. Blumental, W. L. Hale, and W. F. Lever. 1967. Basement zone antibodies in bullous pemphigoid. JAMA 200: 751-756.
2. Tsuji-Abe, Y., M. Akiyama, Y. Yamanaka, T. Kikuchi, K. C. Sato-Matsumura, and H. Shimizu. 2005. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J. Dermatol. Sci. 37: 145-149.
3. Schmidt, E., K. Obe, E. B. Bröcker, and D. Zillikens. 2000. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch. Dermatol. 136: 174-178.
4. Amo, Y., T. Ohkawa, M. Tatsuta, Y. Hamada, T. Fujimura, K. Katsuoka, and T. Hashimoto. 2001. Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J. Dermatol. Sci. 26: 14-18.
5. Hofmann, S., S. Thoma-Uszynski, T. Hunziker, P. Bernard, C. Koebnick, A. Stauber, G. Schuler, L. Borradori, and M. Hertl. 2002. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J. Invest. Dermatol. 119: 1065-1073.
6. Nishie, W., D. Sawamura, M. Goto, K. Ito, A. Shibaki, J. R. McMillan, K. Sakai, H. Nakamura, E. Olasz, K. B. Yancey, et al. 2007. Humanization of autoantigen. Nat. Med. 13: 378-383.
7. Liu, Z., W. Sui, M. Zhao, Z. Li, N. Li, R. Thresher, G. J. Giudice, J. A. Fairley, C. Sitaru, D. Zillikens, et al. 2008. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J. Autoimmun. 31: 331-338.
8. Sitaru, C., S. Mihai, C. Otto, M. T. Chiriac, I. Hausser, B. Dotterweich, H. Saito, C. Rose, A. Ishiko, and D. Zillikens. 2005. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J. Clin. Invest. 115: 870-878.
9. Sitaru, C., E. Schmidt, S. Petermann, L. S. Munteanu, E. B. Bröcker, and D. Zillikens. 2002. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J. Invest. Dermatol. 118: 664-671.
10. Giudice, G. J., D. J. Emery, B. D. Zelickson, G. J. Anhalt, Z. Liu, and L. A. Diaz. 1993. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J. Immunol. 151: 5742-5750.
11. Zillikens, D., P. A. Rose, S. D. Balding, Z. Liu, M. Olague-Marchan, L. A. Diaz, and G. J. Giudice. 1997. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J. Invest. Dermatol. 109: 573-579.
12. Fairley, J. A., C. L. Fu, and G. J. Giudice. 2005. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. J. Invest. Dermatol. 125: 467-472.
13. Liu, Z., L. A. Diaz, S. J. Swartz, J. L. Troy, J. A. Fairley, and G. J. Giudice. 1995. Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J. Immunol. 155: 5449-5454.
14. Liu, Z., L. A. Diaz, J. L. Troy, A. F. Taylor, D. J. Emery, J. A. Fairley, and G. J. Giudice. 1993. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J. Clin. Invest. 92: 2480-2488.
15. Christophoridis, S., L. Büdinger, L. Borradori, T. Hunziker, H. F. Merk, and M. Hertl. 2000. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br. J. Dermatol. 143: 349-355.
16. Döpp, R., E. Schmidt, I. Chimanovitch, M. Leverkus, E. B. Bröcker, and D. Zillikens. 2000. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J. Am. Acad. Dermatol. 42: 577-583.
17. Dimson, O. G., G. J. Giudice, C. L. Fu, F. Van den Bergh, S. J. Warren, M. M. Janson, and J. A. Fairley. 2003. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J. Invest. Dermatol. 120: 784-788.
18. Messingham, K. A., M. H. Noe, M. A. Chapman, G. J. Giudice, and J. A. Fairley. 2009. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J. Immunol. Methods 346: 18-25.
19. Fairley, J. A., C. T. Burnett, C.-L. Fu, D. L. Larson, M. G. Fleming, and G. J. Giudice. 2007. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J. Invest. Dermatol. 127: 2605-2611.
20. Fairley, J. A., C. L. Baum, D. S. Brandt, and K. A. Messingham. 2009. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J. Allergy Clin. Immunol. 123: 704-705.
21. Zone, J. J., T. Taylor, C. Hull, L. Schmidt, and L. Meyer. 2007. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J. Invest. Dermatol. 127: 1167-1174.
22. Liu, Z., G. J. Giudice, S. J. Swartz, J. A. Fairley, G. O. Till, J. L. Troy, and L. A. Diaz. 1995. The role of complement in experimental bullous pemphigoid. J. Clin. Invest. 95: 1539-1544.
23. Chen, R., G. Ning, M. L. Zhao, M. G. Fleming, L. A. Diaz, Z. Werb, and Z. Liu. 2001. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J. Clin. Invest. 108: 1151-1158.
24. Liu, Z., G. J. Giudice, X. Zhou, S. J. Swartz, J. L. Troy, J. A. Fairley, G. O. Till, and L. A. Diaz. 1997. A major role for neutrophils in experimental bullous pemphigoid. J. Clin. Invest. 100: 1256-1263.
25. Veri, M. C., S. Gorlatov, H. Li, S. Burke, S. Johnson, J. Stavenhagen, K. E. Stein, E. Bonvini, and S. Koenig. 2007. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121: 392-404. (Pubitemid 46817361)
26. Li, M., U. Wirthmueller, and J. V. Ravetch. 1996. Reconstitution of human Fc gamma RIII cell type specificity in transgenic mice. J. Exp. Med. 183: 1259-1263.
27. Nimmerjahn, F., and J. V. Ravetch. 2008. Analyzing antibody-Fc-receptor interactions. Methods Mol. Biol. 415: 151-162.
28. Sitaru, C., and D. Zillikens. 2005. Mechanisms of blister induction by autoantibodies. Exp. Dermatol. 14: 861-875.
29. Yu, X., K. Holdorf, B. Kasper, D. Zillikens, R. J. Ludwig, and F. Petersen. 2010. FcgRIIA and FcgRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid. J. Invest. Dermatol. 130: 2841-2844.
30. Schmidt, E., S. Reimer, N. Kruse, S. Jainta, E. B. Bröcker, M. P. Marinkovich, G. J. Giudice, and D. Zillikens. 2000. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J. Invest. Dermatol. 115: 842-848.
31. Schmidt, E., A. Ambach, B. Bastian, E. B. Bröcker, and D. Zillikens. 1996. Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. J. Am. Acad. Dermatol. 34: 310-312.
32. Schmidt, E., B. Bastian, R. Dummer, H. P. Tony, E. B. Bröcker, and D. Zillikens. 1996. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch. Dermatol. Res. 288: 353-357.
33. Kitajima, Y., M. Nojiri, T. Yamada, Y. Hirako, and K. Owaribe. 1998. Internalization of the 180 kDa bullous pemphigoid antigen as immune complexes in basal keratinocytes: an important early event in blister formation in bullous pemphigoid. Br. J. Dermatol. 138: 71-76.
34. Iwata, H., N. Kamio, Y. Aoyama, Y. Yamamoto, Y. Hirako, K. Owaribe, and Y. Kitajima. 2009. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J. Invest. Dermatol. 129: 919-926.
35. Jonkman, M. F., M. C. de Jong, K. Heeres, H. H. Pas, J. B. van der Meer, K. Owaribe, A. M. Martinez de Velasco, C. M. Niessen, and A. Sonnenberg. 1995. 180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosa. J. Clin. Invest. 95: 1345-1352.
36. Varani, J., S. E. Fligiel, L. Schuger, P. Perone, D. Inman, C. E. Griffiths, and J. J. Voorhees. 1993. Effects of all-trans retinoic acid and Ca++ on human skin in organ culture. Am. J. Pathol. 142: 189-198.
37. Iwata, Y., K. Komura, M. Kodera, T. Usuda, Y. Yokoyama, T. Hara, E. Muroi, F. Ogawa, M. Takenaka, and S. Sato. 2008. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch. Dermatol. 144: 41-48.
38. Balding, S. D., L. A. Diaz, and G. J. Giudice. 1997. A recombinant form of the human BP180 ectodomain forms a collagen-like homotrimeric complex. Biochemistry 36: 8821-8830.
39. Kitajima, Y., Y. Hirako, K. Owaribe, and H. Yaoita. 1994. A possible cellbiologic mechanism involved in blister formation of bullous pemphigoid: anti-180-kD BPA antibody is an initiator. Dermatology (Basel) 189(Suppl 1): 46-49. (Pubitemid 24141426)
40. Provost, T. T., and T. B. Tomasi Jr. 1974. Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin. Exp. Immunol. 18: 193-200.
41. Sato, M., H. Shimizu, A. Ishiko, T. Masunaga, M. Akiyama, T. Hashimoto, Y. Kitajima, and T. Nishikawa. 1998. Precise ultrastructural localization of in vivo deposited IgG antibodies in fresh perilesional skin of patients with bullous pemphigoid. Br. J. Dermatol. 138: 965-971.
42. Schmidt, E., S. Reimer, N. Kruse, E. B. Bröcker, and D. Zillikens. 2001. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin. Exp. Immunol. 124: 157-162.
43. van der Wier, G., H. H. Pas, and M. F. Jonkman. 2010. Experimental human cell and tissue models of pemphigus. Dermatol. Res. Pract. 2010: 143871.
44. Companjen, A. R., L. I. van der Wel, L. Wei, J. D. Laman, and E. P. Prens. 2001. A modified ex vivo skin organ culture system for functional studies. Arch. Dermatol. Res. 293: 184-190.
45. Zhao, M., M. E. Trimbeger, N. Li, L. A. Diaz, S. D. Shapiro, and Z. Liu. 2006. Role of FcRs in animal model of autoimmune bullous pemphigoid. J. Immunol. 177: 3398-3405. (Pubitemid 44277860)
46. Zhao, W., C. L. Kepley, P. A. Morel, L. M. Okumoto, Y. Fukuoka, and L. B. Schwartz. 2006. Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells. J. Immunol. 177: 694-701.
47. D'Auria, L., P. Cordiali Fei, and F. Ameglio. 1999. Cytokines and bullous pemphigoid. Eur. Cytokine Netw. 10: 123-134.
48. Ameglio, F., L.D'Auria, C. Bonifati, C. Ferraro, A. Mastroianni, and B. Giacalone. 1998. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br. J. Dermatol. 138: 611-614.
49. McGrath, J. A., T. Darling, B. Gatalica, G. Pohla-Gubo, H. Hintner, A. M. Christiano, K. Yancey, and J. Uitto. 1996. A homozygous deletion mutation in the gene encoding the 180-kDa bullous pemphigoid antigen (BPAG2) in a family with generalized atrophic benign epidermolysis bullosa. J. Invest. Dermatol. 106: 771-774.
50. Van den Bergh, F., S. L. Eliason, and G. J. Giudice. 2011. Type XVII collagen (BP180) can function as a cell-matrix adhesion molecule via binding to laminin 332. Matrix Biol. 30: 100-108.
51. Sitaru, C. 2009. Bullous pemphigoid: a prototypical antibody-mediated organ-specific autoimmune disease. J. Invest. Dermatol. 129: 822-824.